Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study

Basit Öğe Kaydı
dc.WoS.categoriesOncologyen_US
dc.authorid0000-0003-0917-2098en_US
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorÖzmen, Tolga
dc.contributor.authorDuymaz, Tomris
dc.date.accessioned2024-04-16T09:24:38Z
dc.date.available2024-04-16T09:24:38Z
dc.date.issued2023-10
dc.description.abstractEstradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in pre-menopausal women. Studies have shown that AMH levels are more sensitive than those of E2, FSH, and inhibin B and that AFC and MOV can be used to evaluate ovarian reserve. AMH, AFC, and MOV measurements were performed before and after adjuvant SC in 3-month periods for one year. Patients were classified as experiencing chemotherapy-induced amenorrhea (CIA) if they did not have menstrual cycles for a period of six months or longer following the conclusion of their chemotherapy treatment. We aimed to evaluate the factors affecting chemotherapy-induced amenorrhea in breast cancer patients treated with adjuvant chemotherapy and the performance of baseline measurements of AMH, AFC, and MOV to predict chemotherapy-induced amenorrhea. The effects of different chemotherapy regimens on the AMH level, AFC, and MOV in CIA patients were investigated. Seventy-one patients were eligible for this study, and the median age was 38 years (range: 23–45). The median follow-up was 37 months (range: 20–51), and CIA developed in 62% of the patients. The AMH level and AFC were significantly decreased one year after SC (p < 0.0001), whereas MOV was not (p = 0.507). AMH levels before chemotherapy (median: 1.520 vs. 0.755, p = 0.001) and at the end of the first year (median: 0.073 vs. 0.010, p = 0.030) and pre-treatment AFC (median: 12 vs. 4.50, p = 0.026) were lower in patients with CIA compared to those without CIA. The AMH levels before SC were the most valuable and earliest factor for predicting CIA development. In addition, there was no difference between the chemotherapy regimens (including or not including taxane) in terms of CIA development.en_US
dc.fullTextLevelFull Texten_US
dc.identifier.doi10.3390/curroncol30100666en_US
dc.identifier.issn1718-7729
dc.identifier.issn1198-0052
dc.identifier.pmid37887566en_US
dc.identifier.scopus2-s2.0-85175078112en_US
dc.identifier.urihttps://hdl.handle.net/11411/5260
dc.identifier.urihttps://doi.org/10.3390/curroncol30100666
dc.identifier.wosWOS:001098328900001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.issue10en_US
dc.language.isoenen_US
dc.nationalInternationalen_US
dc.numberofauthors10+en_US
dc.pages9217-9229en_US
dc.publisherMDPIen_US
dc.relation.ispartofCURRENT ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectanti-mullerian hormoneen_US
dc.subjectantral follicle countsen_US
dc.subjectbreast canceren_US
dc.subjectchemotherapy-induced amenorrheaen_US
dc.subjectmedian ovarian volumesen_US
dc.subjectovarian reserveen_US
dc.titleEvaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Studyen_US
dc.typeArticleen_US
dc.volume30en_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
2023WosDuymaz.pdf
Boyut:
949.67 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Faculty of Health Sciences
PubMed Indexed Publications
Scopus Indexed Publications
Web of Science Indexed Publications